AbbVie Inc.
AbbVie Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
3 of 4 strong
The short version
- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum. - AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance.
From AbbVie Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum.
- Total net revenues expected at approximately $67.3 billion, up $300 million from prior forecast.
- Skyrizi global revenues projected at $21.6 billion, up $100 million, driven by psoriatic and IBD growth.
- Rinvoq global sales forecast at $10.2 billion, up $100 million with strong performance in rheumatoid and gastro indications.
- Neuroscience segment revenues expected to reach $12.6 billion, up $100 million due to portfolio momentum.
- Immunology and neuroscience are delivering high double-digit growth, many assets growing north of 20%.
- Skyrizi and Rinvoq expected to exceed peak sell-side consensus forecasts.
- Oncology pipeline assets and obesity programs contribute to growth outlook.
2 more points from AbbVie Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what AbbVie Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- AbbVie announced several new manufacturing site constructions as part of a $100 billion commitment to U.S. R&D and capital investments over the next decade.
- $1.4 billion investment to build a pharmaceutical manufacturing campus in North Carolina.
- $380 million investment for two new plants in North Chicago.
- These strategic investments aim to strengthen AbbVie’s ability to produce medical breakthroughs in immunology, neuroscience, oncology, and obesity.
2 more points from AbbVie Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what AbbVie Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
What AbbVie Inc.'s management said in earlier quarters
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
AbbVie Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were AbbVie Inc. Q2 FY26 results?
- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum. - AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance.
What is AbbVie Inc. share price analysis?
AbbVie Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 104.0 with a market cap of $386,274. Investors should review the full earnings analysis for detailed insights.
Is AbbVie Inc. planning capital expenditure?
- AbbVie announced several new manufacturing site constructions as part of a $100 billion commitment to U.S.
Keep AbbVie Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.